No Data
No Data
InnoCare Pharma Agrees With US FDA For Phase 3 Clinical Trail of Orelabrutinib for PPMS Patients; Shanghai Shares Up 4%
HK Stocks Movement | Innocare (09969) surged more than 8% as the clinical research of Aprepitant in the USA Phase III was approved.
Innocare (09969) rose over 8% and as of the time of publication, it was up 8.32% at HKD 5.6, with a turnover of HKD 13.0947 million.
InnoCare Advances MS Treatment Into Phase 3 Trials
Hong Kong Stock Exchange Announcement: Innocare and FDA have reached an agreement to initiate Phase III study for the treatment of primary progressive multiple sclerosis (PPMS) patients with Obrutinib.
Innocare has reached an agreement with the FDA on the initiation of phase III study for the treatment of primary progressive multiple sclerosis (PPMS) patients with Ocrelizumab; jd.com logistics and Dada have entered into a freight service framework agreement.
InnoCare Pharma Ltd. (9969) Gets a Buy From Jefferies
Innocare (09969) has cancelled 1.65 million repurchased shares.
Innocare (09969) announced that on August 29, 2024, the company cancelled 1.65 million shares that had been repurchased...
No Data